MA28171A1 - Derives de tetrazole et methodes de traitement de troubles lies au metabolisme - Google Patents

Derives de tetrazole et methodes de traitement de troubles lies au metabolisme

Info

Publication number
MA28171A1
MA28171A1 MA29049A MA29049A MA28171A1 MA 28171 A1 MA28171 A1 MA 28171A1 MA 29049 A MA29049 A MA 29049A MA 29049 A MA29049 A MA 29049A MA 28171 A1 MA28171 A1 MA 28171A1
Authority
MA
Morocco
Prior art keywords
inhibitors
compounds
present
treatment
methods
Prior art date
Application number
MA29049A
Other languages
English (en)
French (fr)
Inventor
Graeme Semple
Thomas Schrader
Philip J Skinner
Steven L Colleti
Tawfik Gharbaoui
Jason E Imbriglio
Jae-Kyu Jung
Rui Liang
Subharekha Raghavan
Darby Schmidt
James R Tata
Original Assignee
Arena Pharm Inc
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc, Merck & Co Inc filed Critical Arena Pharm Inc
Publication of MA28171A1 publication Critical patent/MA28171A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA29049A 2003-10-31 2006-05-23 Derives de tetrazole et methodes de traitement de troubles lies au metabolisme MA28171A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51623803P 2003-10-31 2003-10-31

Publications (1)

Publication Number Publication Date
MA28171A1 true MA28171A1 (fr) 2006-09-01

Family

ID=34572875

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29049A MA28171A1 (fr) 2003-10-31 2006-05-23 Derives de tetrazole et methodes de traitement de troubles lies au metabolisme

Country Status (37)

Country Link
US (2) US8637555B2 (enExample)
EP (2) EP1599469B1 (enExample)
JP (2) JP4533898B2 (enExample)
KR (1) KR100850591B1 (enExample)
CN (1) CN1867562B (enExample)
AR (1) AR046611A1 (enExample)
AT (1) ATE328880T1 (enExample)
AU (1) AU2004287861B2 (enExample)
BR (1) BRPI0415631A (enExample)
CA (1) CA2539985C (enExample)
CO (1) CO5690551A2 (enExample)
CR (1) CR8270A (enExample)
CY (1) CY1105479T1 (enExample)
DE (1) DE602004001134T2 (enExample)
DK (1) DK1599469T3 (enExample)
EA (1) EA011484B1 (enExample)
EC (1) ECSP066529A (enExample)
ES (1) ES2267077T3 (enExample)
GE (1) GEP20094801B (enExample)
HR (1) HRP20060286T3 (enExample)
IL (1) IL174042A0 (enExample)
IS (1) IS2372B (enExample)
MA (1) MA28171A1 (enExample)
MX (1) MXPA06004556A (enExample)
MY (1) MY140410A (enExample)
NO (1) NO20062509L (enExample)
NZ (1) NZ546285A (enExample)
PE (1) PE20050483A1 (enExample)
PL (1) PL1599469T3 (enExample)
PT (1) PT1599469E (enExample)
RS (1) RS20060290A (enExample)
SI (1) SI1599469T1 (enExample)
TN (1) TNSN06150A1 (enExample)
TW (1) TWI258478B (enExample)
UA (1) UA86783C2 (enExample)
WO (1) WO2005044816A1 (enExample)
ZA (2) ZA200603419B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083388A2 (en) 2003-03-14 2004-09-30 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
AU2004293415A1 (en) 2003-11-21 2005-06-09 Arena Pharmaceuticals, Inc. 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
WO2006026273A2 (en) * 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
JP2008519080A (ja) * 2004-11-05 2008-06-05 アリーナ ファーマシューティカルズ， インコーポレイテッド ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8168799B2 (en) 2005-04-28 2012-05-01 Merck Sharpe & Dohme Ltd. Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles
SI1901731T1 (sl) 2005-06-28 2011-07-29 Merck Sharp & Dohme Niacin receptorski antagonisti, sestavki vsebujoäśi take spojine in postopki zdravljenja
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico
HK1217488A1 (zh) 2013-02-21 2017-01-13 Adverio Pharma Gmbh {4,6-二氨基-2-[1-(2-氟苄基)-1h-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
US9975910B2 (en) 2013-07-23 2018-05-22 Eisai R&D Management Co., Ltd. Hetero-fused cyclic compound
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
CA3096145A1 (en) * 2019-10-11 2021-04-11 Royal Bank Of Canada System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178263A (ja) * 1988-12-27 1990-07-11 Kaken Pharmaceut Co Ltd アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en) 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
EP0946508B1 (en) 1996-12-23 2009-09-23 Bristol-Myers Squibb Pharma Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
NZ521192A (en) 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
WO2003022814A1 (en) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Indole derivatives
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
KR20030017569A (ko) 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
AU7307101A (en) 2000-06-30 2002-01-14 Glaxo Group Ltd Quinazoline ditosylate salt compounds
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
BR0210102A (pt) 2001-06-01 2004-06-08 Hoffmann La Roche Derivados de pirimidina, triazina e pirazina como receptores de glutamato
JP4510442B2 (ja) 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
DE60200346T2 (de) 2001-06-27 2005-03-24 Rs Tech Corp. Neuer chiraler salen-katalysator und verfahren zur herstellung chiraler verbindungen aus racemischen epoxiden unter verwendung des neuen katalysators
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
MXPA04009095A (es) 2002-03-19 2004-12-06 Ono Pharmaceutical Co Compuesto de acido carboxilico y agente farmaceutico que comprende el compuesto como ingrediente activo.
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
CA2501134A1 (en) * 2002-10-10 2004-04-22 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005011677A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
PE20050483A1 (es) * 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CN101103030B (zh) 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
WO2006026273A2 (en) 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
JP2008519080A (ja) 2004-11-05 2008-06-05 アリーナ ファーマシューティカルズ， インコーポレイテッド ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8168799B2 (en) 2005-04-28 2012-05-01 Merck Sharpe & Dohme Ltd. Process for the preparation of tetrazolytetrahydrocyclopentapyrazoles

Also Published As

Publication number Publication date
EP1683794A1 (en) 2006-07-26
ZA200606203B (en) 2007-04-25
EP1599469A1 (en) 2005-11-30
US20070072924A1 (en) 2007-03-29
ATE328880T1 (de) 2006-06-15
HRP20060286T3 (en) 2007-03-31
TWI258478B (en) 2006-07-21
EP1599469B1 (en) 2006-06-07
NZ546285A (en) 2010-04-30
TW200530221A (en) 2005-09-16
WO2005044816A1 (en) 2005-05-19
MXPA06004556A (es) 2006-07-06
MY140410A (en) 2009-12-31
AU2004287861B2 (en) 2008-08-14
HK1076468A1 (en) 2006-01-20
EA011484B1 (ru) 2009-04-28
DE602004001134T2 (de) 2007-04-19
JP2010163448A (ja) 2010-07-29
AU2004287861A1 (en) 2005-05-19
ZA200603419B (en) 2006-10-25
UA86783C2 (ru) 2009-05-25
PL1599469T3 (pl) 2006-10-31
RS20060290A (sr) 2008-11-28
PE20050483A1 (es) 2005-08-25
BRPI0415631A (pt) 2006-12-12
KR20060073974A (ko) 2006-06-29
ES2267077T3 (es) 2007-03-01
CY1105479T1 (el) 2010-07-28
CN1867562A (zh) 2006-11-22
CN1867562B (zh) 2011-07-13
DE602004001134D1 (de) 2006-07-20
IL174042A0 (en) 2006-08-01
IS2372B (is) 2008-06-15
DK1599469T3 (da) 2006-10-09
KR100850591B1 (ko) 2008-08-05
GEP20094801B (en) 2009-10-26
SI1599469T1 (sl) 2006-10-31
PT1599469E (pt) 2006-10-31
EA200600879A1 (ru) 2006-10-27
IS8481A (is) 2006-05-24
NO20062509L (no) 2006-06-26
AR046611A1 (es) 2005-12-14
JP4533898B2 (ja) 2010-09-01
US8637555B2 (en) 2014-01-28
TNSN06150A1 (en) 2007-11-15
CA2539985C (en) 2010-02-16
JP2007509181A (ja) 2007-04-12
US20060217562A1 (en) 2006-09-28
CA2539985A1 (en) 2005-05-19
ECSP066529A (es) 2006-10-10
CR8270A (es) 2006-10-06
CO5690551A2 (es) 2006-10-31

Similar Documents

Publication Publication Date Title
MA28171A1 (fr) Derives de tetrazole et methodes de traitement de troubles lies au metabolisme
MA29148B1 (fr) Derives de pyrazole condenses, et procedes pour traiter des troubles lies au metabolisme
WO2004033431A3 (en) Hydroxypyrazoles for use against metabolic-related disorders
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1
MA33528B1 (fr) Derives pyridin-4-yliques
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA27317A1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
MA31373B1 (fr) Composes amino-heterocycliques
MA27452A1 (fr) Derives d'indole servant d'agonistes beta-2
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA31466B1 (fr) Derives de benzimidazole
TNSN06360A1 (fr) 4-phenylamino-quinazoline-6-yl-amides
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
MA27439A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA27190A1 (fr) Derives de tropane servant de modulateurs de ccr5
TNSN06347A1 (fr) Derives de morpholine
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
MA29566B1 (fr) Composes chimiques
MA27852A1 (fr) Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique
DE60327446D1 (de) 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie